Tags

Type your tag names separated by a space and hit enter

Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Eur J Gastroenterol Hepatol. 2008 Jul; 20(7):680-7.EJ

Abstract

OBJECTIVE

The objective of this study was to compare the efficacy of anti-hepatitis C virus (anti-HCV) treatment schedules on the basis of an early virological response (EVR), defined as undetectable serum HCV-RNA (<50 IU/ml) after a 12-week induction course of peginterferon alpha-2a (PEG-IFN) 180 mcg/week.

METHODS

A total of 210 interferon-naïve patients (69% male; median age, 42 years) with histologically proven chronic hepatitis C infection (genotype 1: 62%) received PEG-IFN 180 mcg/week for 12 weeks. Patients with EVR (58%) were randomized to continue PEG-IFN monotherapy (n=64) or to add ribavirin (RBV), 800 mg/day (n=57), for 36 additional weeks. Patients without EVR (42%) were randomized to add RBV (n=42), or RBV plus amantadine, 200 mg/day (n=47), for 36 additional weeks. Sustained virological response (SVR, undetectable HCV-RNA 24 weeks after treatment completion) was compared among treatment groups.

RESULTS

Patients with EVR: SVR rate was 60.3% in the PEG-IFN group versus 67.2% in the PEG-IFN+RBV group (NS). In genotypes 2/3, SVR rates were 66.7 versus 73.1% (NS); in genotypes 1/4, SVR rates were 51.6 versus 61.3%, respectively (NS). Patients without EVR: SVR was 16.7% in the PEG-IFN+RBV group versus 31.9% in the triple therapy group (P=0.07). In patients with genotypes 1/4, SVR rates were 9.4 versus 29.7% (P=0.041).

CONCLUSION

In genotypes 1/4 patients without EVR, triple therapy results in higher SVR rates than standard dual therapy. This study confirms that addition of amantadine is beneficial in early-recognized 'difficult-to-treat' patients.

Authors+Show Affiliations

Hepatology Unit, Tor Vergata University, Rome, Italy. angelico@med.uniroma2.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18679072

Citation

Angelico, Mario, et al. "Peginterferon Alpha-2a and Ribavirin Versus Peginterferon Alpha-2a Monotherapy in Early Virological Responders and Peginterferon Alpha-2a and Ribavirin Versus Peginterferon Alpha-2a, Ribavirin and Amantadine Triple Therapy in Early Virological Nonresponders: the SMIEC II Trial in Naïve Patients With Chronic Hepatitis C." European Journal of Gastroenterology & Hepatology, vol. 20, no. 7, 2008, pp. 680-7.
Angelico M, Koehler-Horst B, Piccolo P, et al. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 2008;20(7):680-7.
Angelico, M., Koehler-Horst, B., Piccolo, P., Angelico, F., Gentile, S., Francioso, S., Tarquini, P., Vecchia, R. D., Ponti, L., Pilleri, G., Barlattani, A., Grieco, A., Soccorsi, F., Guarascio, P., Demelia, L., Sorbello, O., Rossi, Z., Forlini, G., Zaru, S., & Bandiera, F. (2008). Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C. European Journal of Gastroenterology & Hepatology, 20(7), 680-7. https://doi.org/10.1097/MEG.0b013e3282f5196c
Angelico M, et al. Peginterferon Alpha-2a and Ribavirin Versus Peginterferon Alpha-2a Monotherapy in Early Virological Responders and Peginterferon Alpha-2a and Ribavirin Versus Peginterferon Alpha-2a, Ribavirin and Amantadine Triple Therapy in Early Virological Nonresponders: the SMIEC II Trial in Naïve Patients With Chronic Hepatitis C. Eur J Gastroenterol Hepatol. 2008;20(7):680-7. PubMed PMID: 18679072.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C. AU - Angelico,Mario, AU - Koehler-Horst,Beate, AU - Piccolo,Paola, AU - Angelico,Francesco, AU - Gentile,Silvia, AU - Francioso,Simona, AU - Tarquini,Pierluigi, AU - Vecchia,Roberto Della, AU - Ponti,Laura, AU - Pilleri,Giampaolo, AU - Barlattani,Angelo, AU - Grieco,Antonio, AU - Soccorsi,Francesco, AU - Guarascio,Paolo, AU - Demelia,Luigi, AU - Sorbello,Orazio, AU - Rossi,Zaccaria, AU - Forlini,Giuseppe, AU - Zaru,Salvatore, AU - Bandiera,Franco, AU - ,, PY - 2008/8/6/pubmed PY - 2009/3/17/medline PY - 2008/8/6/entrez SP - 680 EP - 7 JF - European journal of gastroenterology & hepatology JO - Eur J Gastroenterol Hepatol VL - 20 IS - 7 N2 - OBJECTIVE: The objective of this study was to compare the efficacy of anti-hepatitis C virus (anti-HCV) treatment schedules on the basis of an early virological response (EVR), defined as undetectable serum HCV-RNA (<50 IU/ml) after a 12-week induction course of peginterferon alpha-2a (PEG-IFN) 180 mcg/week. METHODS: A total of 210 interferon-naïve patients (69% male; median age, 42 years) with histologically proven chronic hepatitis C infection (genotype 1: 62%) received PEG-IFN 180 mcg/week for 12 weeks. Patients with EVR (58%) were randomized to continue PEG-IFN monotherapy (n=64) or to add ribavirin (RBV), 800 mg/day (n=57), for 36 additional weeks. Patients without EVR (42%) were randomized to add RBV (n=42), or RBV plus amantadine, 200 mg/day (n=47), for 36 additional weeks. Sustained virological response (SVR, undetectable HCV-RNA 24 weeks after treatment completion) was compared among treatment groups. RESULTS: Patients with EVR: SVR rate was 60.3% in the PEG-IFN group versus 67.2% in the PEG-IFN+RBV group (NS). In genotypes 2/3, SVR rates were 66.7 versus 73.1% (NS); in genotypes 1/4, SVR rates were 51.6 versus 61.3%, respectively (NS). Patients without EVR: SVR was 16.7% in the PEG-IFN+RBV group versus 31.9% in the triple therapy group (P=0.07). In patients with genotypes 1/4, SVR rates were 9.4 versus 29.7% (P=0.041). CONCLUSION: In genotypes 1/4 patients without EVR, triple therapy results in higher SVR rates than standard dual therapy. This study confirms that addition of amantadine is beneficial in early-recognized 'difficult-to-treat' patients. SN - 0954-691X UR - https://www.unboundmedicine.com/medline/citation/18679072/Peginterferon_alpha_2a_and_ribavirin_versus_peginterferon_alpha_2a_monotherapy_in_early_virological_responders_and_peginterferon_alpha_2a_and_ribavirin_versus_peginterferon_alpha_2a_ribavirin_and_amantadine_triple_therapy_in_early_virological_nonresponders:_the_SMIEC_II_trial_in_naïve_patients_with_chronic_hepatitis_C_ L2 - http://dx.doi.org/10.1097/MEG.0b013e3282f5196c DB - PRIME DP - Unbound Medicine ER -